The 42nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID 2024)

Copenhagen, Denmark 20 May 2024 - 24 May 2024

Glecaprevir/pibrentasvir shows favourable efficacy signals for paediatric HCV

10 Jul 2024 by

Findings from the ongoing POLAC project demonstrate that treatment with the pangenotypic regimen comprising glecaprevir/pibrentasvir (GLE/PIB) for 8 weeks is highly effective against chronic hepatitis C virus (HCV) infection in children and adolescents. This regimen also showed a good safety profile.

Glecaprevir/pibrentasvir shows favourable efficacy signals for paediatric HCV

10 Jul 2024

Retrospective study validates nirsevimab role against RSV in infants

08 Jul 2024 by

A retrospective cohort study evaluating participants from Catalonia, Spain reinforces the potential of immunoprophylaxis with the novel monoclonal antibody nirsevimab in combating respiratory syncytial virus (RSV)-related outcomes in infants in the hospital and primary care settings.

Retrospective study validates nirsevimab role against RSV in infants

08 Jul 2024